Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT (2022) Sureda A, Boumendil A, Berning P, Finel H, Caillot D, Rösler W, Finke J, et al. Conference contribution CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany (2022) Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CD, Buecklein VL, Bonig H, et al. Conference contribution Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis (2022) Biedermann A, Mangelberger-Eberl D, Mougiakakos D, Büttner-Herold M, Flamann C, Kellner C, Altmeyer S, et al. Conference contribution Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy (2022) Reimann H, Kremer A, Blumenberg V, Schmidt K, Aigner M, Kremer A, Tenbusch M, et al. Conference contribution Detection of Signature Double-Negative T Cells Is a Reliable Marker for ALPS Associated with FAS Mutation (2022) Eisenhauer N, Miano M, Naumann-Bartsch N, Leyh J, Terranova P, Hinze C, Aigner M, et al. Conference contribution Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL (2022) Blumenberg V, Busch G, Baumann S, Jitschin R, Winkelmann M, Hellwig K, Rejeski K, et al. Conference contribution Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial (2022) Roellig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Haenel M, et al. Conference contribution Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group (2022) Burchert A, Saussele S, Michel C, Metzelder SK, Hochhaus A, Gattermann N, Crysandt M, et al. Conference contribution Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma (2022) Straka C, Schaefer-Eckart K, Hertenstein B, Bassermann F, Salwender H, Langer C, Kroenke J, et al. Conference contribution Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry (2022) Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, et al. Conference contribution